Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Merck: Cutbacks, But In A New Building


In Business This Week

MERCK: CUTBACKS, BUT IN A NEW BUILDING

Roy Vagelos wasn't kidding. Last fall, the Merck CEO warned of a "highly pressurized" decade for drug companies. Investor worries have shaved more than a third off Merck's stock market value since early last year, and company earnings are being squeezed by slack sales of such key drugs as its new prostate-disease-fighter Proscar and anticholesterol medicine Mevacor. Now, Vagelos is moving to stem the damage by cutting 1,000 jobs, or 2.6% of Merck's work force, this year. Top execs will take pay cuts of up to 10%. The irony: Merck's gleaming new $228 million headquarters complex.EDITED BY KEITH H. HAMMONDS


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus